PureTech

Join us at #ATS2026! We’ll detail SURPASS-IPF (first industry-sponsored, head-to-head, Ph3 superiority #IPF trial) & insights on the translatability of our Ph2b data. So proud of our Celea colleagues who are advancing deupirfenidone as a potential new SOC bit.ly/4nm7a0I

Today we announced our 2025 Full Year Results and Annual Report, highlighting continued progress across our Portfolio with a sharpened strategic focus on disciplined capital allocation, operational efficiency, & long-term value creation. Join us at 9AM EDT/2PM BST as we discuss how PureTech is positioned for the future bit.ly/3R7xJL2

We’re pleased to share positive topline data from Ph1b trial of LYT-200 in relapsed/refractory (R/R) high-risk #MyelodysplasticSyndrome & R/R #AcuteMyeloidLeukemia. Our Founded Entity, Gallop Oncology, intends to discuss next steps w/ FDA in R/R HR-MDS. bit.ly/4mMpnVd

Now published in @ATSBlueEditor: full results from the Phase 2b ELEVATE IPF trial of deupirfenidone These results provide a strong scientific & clinical foundation as our Founded Entity, Celea Therapeutics, prepares to advance deupirfenidone into Phase 3. bit.ly/47Di0sM #idiopathicpulmonaryfibrosis #ipf

Today our Founded Entity @SeaportTx announced the publication of a manuscript that captures the discovery process behind the creation of GlyphAllo, further validating the Glyph platform. Initially advanced at PureTech, GlyphAllo is a hallmark of our strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation.

On #RareDiseaseDay, the world recognizes & supports those living w/ #rarediseases. At PureTech, this is our focus every day. Today, our team joined @Cycle4Survival to champion rare cancer research – an extension of our work at Gallop Oncology to advance LYT-200 in #AML. The same commitment drives our team at Celea Therapeutics to advance deupirfenidone for pp w/ #IPF. Both programs received Orphan Drug Designation, reflecting the need in these communities & what drives us to deliver on our mission .

Our CEO, Robert Lyne, and Co-founder & President, Eric Elenko, PhD, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. bit.ly/4azs3Rw

During #RareDiseaseMonth, we’re reminded that innovation matters most where options are few. Today we're proud to share that deupirfenidone has received #OrphanDrugDesignation from the FDA and European Commission for #IPF. Read More: bit.ly/4kSPNne

On #InternationalDayofWomenandGirlsInScience, we’re proud to recognize the women shaping the future of PureTech. From advancing new possibilities in #IPF & #AML, to translating ideas into medicines, they exemplify scientific leadership. By amplifying their voices today, we aim to inspire the next gen of #WomenInSTEM #IDWGS

Our CEO, Robert Lyne, and President, Eric Elenko, presented at #JPM26, outlining PureTech’s strategy, portfolio progress, and priorities for the year ahead. Watch the presentation replay here: bit.ly/3YKFeID

Our CEO, Robert Lyne, will present at #JPM26 on Wednesday, January 14th, at 4:30pm PST / 7:30pm EST bit.ly/4soa0oh

Wishing our colleagues, shareholders, and the patients we serve a warm and joyful holiday season. We look forward to continuing our important work together in 2026!

Today we announced the appointment of Robert Lyne as CEO. Rob brings deep familiarity with our programs, people, and model, and will lead PureTech in building on this strong foundation to advance transformative therapies for patients and create value for shareholders bit.ly/3Y1hkZ6

Today we announced the successful completion of the End-of-Ph2 meeting w/ FDA for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis #IPF. The Ph3 SURPASS-IPF trial is on track to start in 1H26 by our newest Founded Entity, Celea Therapeutics. bit.ly/4a3fE8A

We’re proud to share positive initial topline data from the Ph1b trial of LYT-200 in relapsed/refractory #AML & high-risk #MDS. Our Founded Entity, Gallop Oncology, will present additional details tomorrow at #ASH25 bit.ly/3XzOjU7

Happy Thanksgiving from all of us at PureTech!

New data from our Phase 1b trial of LYT-200 in #AML will be presented at #ASH25. Results to date show strong clinical activity + favorable safety in heavily pretreated patients. Matured data to come at ASH & in Q4 2025 bit.ly/4nDvqKt

New analyses presented at #CHEST2025 demonstrate deupirfenidone’s consistent safety & efficacy in people living w/ #IPF, regardless of age. We’re proud to showcase the potential for deupirfenidone to change the treatment paradigm for people w/ IPF bit.ly/4ndhOFr